CTOs on the Move

CG Pharmaceuitcals

www.cgpharma.com

 
CG Pharmaceuitcals is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgpharma.com
  • 5858 Horton St Ste 265
    Emeryville, CA USA 94608
  • Phone: 510.594.8201

Executives

Name Title Contact Details

Similar Companies

Southern Research Institute

Southern Research Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Pendulum Therapeutics

Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one`s health.

Technologie BiolActis

Technologie BiolActis Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.